<DOC>
	<DOCNO>NCT01876420</DOCNO>
	<brief_summary>To assess safety clinical performance CoreValve™ Evolut R™ System .</brief_summary>
	<brief_title>The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study</brief_title>
	<detailed_description>The study objectives assess safety clinical performance CoreValve™ Evolut R™ System patient severe symptomatic aortic stenosis consider high extreme risk surgical aortic valve replacement . These objective accomplish prospective clinical study involve 60 implanted subject among six study center .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Severe aortic stenosis , define aortic valve area &lt; 1.0 cm2 ( aortic valve area index &lt; 0.6 cm2/m2 ) continuity equation , AND mean gradient &gt; 40 mmHg maximal aortic valve velocity &gt; 4.0 m/sec rest echocardiogram . 2 . Estimated 30 day mortality risk &gt; 15 % study center Heart Team assessment,33 OR least two cardiovascular surgeon study center deny surgery prohibitive operative risk , estimate combine &gt; 50 % risk irreversible mortality morbidity . 3 . Symptoms aortic stenosis , NYHA Functional Class II great . 4 . The subject meet legal minimum age provide inform consent base local regulatory requirement , provide write informed consent approve EC/IRB respective clinical site . 5 . The subject treating physician agree subject return require postprocedure followup visit . Clinical exclusion criterion : 6 . Subject offer SAVR decline . 7 . Any condition consider contraindication placement bioprosthetic valve ( e.g . subject indicated mechanical prosthetic valve ) . 8 . Known hypersensitivity contraindication Nitinol . 9 . Blood dyscrasia define : leukopenia ( WBC &lt; 1000 mm3 ) , thrombocytopenia ( platelet count &lt; 50,000 cells/mm3 ) , history bleed diathesis coagulopathy , hypercoagulable state . 10 . Untreated clinically significant coronary artery disease require revascularization . 11 . Severe leave ventricular dysfunction leave ventricular ejection fraction ( LVEF ) &lt; 20 % echocardiography , contrast ventriculography , radionuclide ventriculography . 12 . End stage renal disease require chronic dialysis creatinine clearance &lt; 20 cc/min . 13 . Ongoing sepsis , include active endocarditis . 14 . Any condition consider contraindication extracorporeal assistance . 15 . Any percutaneous coronary peripheral interventional procedure bare metal stent perform within 30 day prior Heart Team assessment , within six month prior Heart Team assessment procedure drug elute stent . 16 . Symptomatic carotid vertebral artery disease successful treatment carotid stenosis within eight week Heart Team Assessment . 17 . Cardiogenic shock manifest low cardiac output , vasopressor dependence , mechanical hemodynamic support . 18 . Recent ( within 6 month Heart Team assessment ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . 19 . Gastrointestinal ( GI ) bleed would preclude anticoagulation . 20 . Subject refuse blood transfusion . 21 . Severe dementia ( result either inability provide inform consent study/procedure , prevents independent lifestyle outside chronic care facility , fundamentally complicate rehabilitation procedure compliance followup visit ) . 22 . Estimated life expectancy le 12 month due associate noncardiac comorbid condition . 23 . Other medical , social , psychological condition opinion Investigator precludes subject appropriate consent adherence protocol require followup exam . 24 . Currently participate investigational drug another device study ( exclude registry ) . 25 . Evidence acute myocardial infarction ≤30 day index procedure . 26 . Need emergency surgery reason . 27 . Liver failure ( ChildC ) . 28 . Subject pregnant breast feeding . Anatomical exclusion criterion : 29 . Preexisting prosthetic heart valve position . 30 . Mixed aortic valve disease ( aortic stenosis moderate severe aortic regurgitation ) . 31 . Severe mitral regurgitation . 32 . Severe tricuspid regurgitation . 33 . Moderate severe mitral stenosis . 34 . Hypertrophic obstructive cardiomyopathy . 35 . Echocardiographic MultiSlice Computed Tomography ( MSCT ) evidence intracardiac mass thrombus vegetation . 36 . Congenital bicuspid unicuspid valve verify echocardiography .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>